Your browser doesn't support javascript.
loading
Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.
Mann, M J; Whittemore, A D; Donaldson, M C; Belkin, M; Conte, M S; Polak, J F; Orav, E J; Ehsan, A; Dell'Acqua, G; Dzau, V J.
Affiliation
  • Mann MJ; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Lancet ; 354(9189): 1493-8, 1999 Oct 30.
Article in En | MEDLINE | ID: mdl-10551494
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Oligonucleotides / Transcription Factors / Genetic Therapy / Carrier Proteins / Cell Cycle Proteins / Blood Vessel Prosthesis Implantation / DNA-Binding Proteins / Graft Occlusion, Vascular Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Lancet Year: 1999 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Oligonucleotides / Transcription Factors / Genetic Therapy / Carrier Proteins / Cell Cycle Proteins / Blood Vessel Prosthesis Implantation / DNA-Binding Proteins / Graft Occlusion, Vascular Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Lancet Year: 1999 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido